iX Biopharma Ltd (42C.SI) has released a July 2026 corporate brief detailing key milestones and strategic initiatives for fiscal year 2026.
The Singapore-listed specialty pharmaceutical company confirmed that on Feb, 2026 it secured a US$41 million development contract from the United States Department of Defense to fund Phase 3 studies of Wafermine, its sublingual racemic ketamine candidate for acute, moderate-to-severe pain. The trial funding will be provided by the DoD’s Office of the Assistant Secretary of Defense for Health Affairs (OPMED), with approximately US$34.3 million allocated to the Phase 3 programme. An Emergency Use Authorization application for battlefield deployment of Wafermine is in progress.
The company reported two equity raises during the period: 6.7 million Singapore dollars in Oct, 25 at S$0.10 per share and 15 million Singapore dollars in Feb, 26 at S$0.198 per share. A joint venture with OSL Compounding 503B was signed in Nov, 25, and the firm plans to relocate its formulation development operations from Australia to the United States in Jun, 26.
iX Biopharma intends to transfer its consumer healthcare activities—comprising around 40 repurposed sublingual formulations, a 503A/503B compounding capability and a telehealth platform focused on longevity and lifestyle—into a new entity named Ligo Pharma. The company aims to commercialise these products in the United States through direct-to-consumer channels and partnerships with compounding pharmacies.
The pharmaceutical pipeline highlighted in the brief includes candidates such as iXB 402 (GLP-1/SGLT2 for obesity/diabetes), BPC-157 for tissue repair, CJC-1295 and Ipamorelin for growth hormone support, and iXB 120 (dexmedetomidine) for agitation in dementia. More than 40 pharmaceutical products are in development across small-molecule and biologic formulations.
iX Biopharma emphasised that its WaferiX sublingual delivery platform and the ongoing advancement of Wafermine remain central to its growth strategy, while the proposed consumer business spinoff is intended to accelerate revenue generation and provide market validation for its differentiated therapies.